{"id":180553,"date":"2024-05-22T15:05:56","date_gmt":"2024-05-22T13:05:56","guid":{"rendered":"https:\/\/clinical.r-biopharm.com\/?p=180553"},"modified":"2024-05-22T15:05:57","modified_gmt":"2024-05-22T13:05:57","slug":"meldepflicht-chlamydia-trachomatis-serotypen-l1-l3","status":"publish","type":"post","link":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/","title":{"rendered":"Meldepflicht Chlamydia trachomatis Serotypen L1- L3"},"content":{"rendered":"\n

Bitte beachten: Der Nachweis der Chlamydia trachomatis Serotypen L1- L3 ist seit September 2022 meldepflichtig<\/p>\n\n\n\n

Wir m\u00f6chten Sie auf die entscheidende Bedeutung der Differenzierung zwischen herk\u00f6mmlichen Chlamydia trachomatis<\/em> Infektionen – und LGV (Lymphogranuloma venereum) <\/em>aufmerksam machen. LGV wird durch die Chlamydia trachomatis<\/em> Serotypen L1 \u2013 L3 ausgel\u00f6st und kann falsch behandelt zu schweren Komplikationen f\u00fchren.<\/p>\n\n\n\n

Warum ist die Differenzierung so wichtig?<\/strong><\/p>\n\n\n\n

    \n
  1. Meldepflicht: <\/strong>Die Detektion der Serotypen L1 \u2013 L3 von Chlamydia trachomatis<\/em> ist seit \u00c4nderung des IfSG im September 2022 meldepflichtig. Eine zeitnahe Meldung ist entscheidend f\u00fcr die \u00dcberwachung und Kontrolle der Ausbreitung.<\/li>\n\n\n\n
  2. Spezifische Diagnostik:<\/strong> Eine spezifische Differenzierung zwischen Chlamydia trachomatis <\/em>und LGV ist nur mit molekularen Testmethoden m\u00f6glich. In Risikogruppen sind im Durchschnitt 30% aller Chlamydien Infektionen auf die Serovare L1 \u2013 L3 zur\u00fcckzuf\u00fchren.<\/li>\n\n\n\n
  3. Verl\u00e4ngerte Behandlungsdauer bei LGV:<\/strong> Im Vergleich zu herk\u00f6mmlichen Chlamydia-Infektionen erfordert LGV eine l\u00e4ngere Antibiotikagabe von bis zu 3 Wochen. Die rechtzeitige und ad\u00e4quate Behandlung minimiert das Risiko von Komplikationen.<\/li>\n<\/ol>\n\n\n\n

    Die Gesundheit der Patienten liegt uns am Herzen:<\/strong> Wir setzen uns daf\u00fcr ein, Ihnen fortschrittliche, umfangreichen TandemPlex\u00ae Panels zur Diagnose und Differenzierung von sexuell-\u00fcbertragbaren-Infektionen anzubieten, um eine gezielte Behandlung zu erm\u00f6glichen.<\/p>\n\n\n\n

    Mehr erfahren<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

    Bitte beachten: Der Nachweis der Chlamydia trachomatis Serotypen L1- L3 ist seit September 2022 meldepflichtig Wir m\u00f6chten Sie auf die entscheidende Bedeutung der Differenzierung zwischen herk\u00f6mmlichen Chlamydia trachomatis Infektionen – und LGV (Lymphogranuloma venereum) aufmerksam machen. LGV wird durch die Chlamydia trachomatis Serotypen L1 \u2013 L3 ausgel\u00f6st und kann falsch behandelt zu schweren Komplikationen f\u00fchren. […]<\/p>\n","protected":false},"author":330,"featured_media":180541,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"54466,86569,61019,33094,75006,173971","_relevanssi_noindex_reason":"","footnotes":""},"categories":[2],"tags":[],"class_list":["post-180553","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sonstige"],"acf":[],"yoast_head":"\nMeldepflicht Chlamydia trachomatis Serotypen L1- L3 - Clinical Diagnostics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Meldepflicht Chlamydia trachomatis Serotypen L1- L3 - Clinical Diagnostics\" \/>\n<meta property=\"og:description\" content=\"Bitte beachten: Der Nachweis der Chlamydia trachomatis Serotypen L1- L3 ist seit September 2022 meldepflichtig Wir m\u00f6chten Sie auf die entscheidende Bedeutung der Differenzierung zwischen herk\u00f6mmlichen Chlamydia trachomatis Infektionen – und LGV (Lymphogranuloma venereum) aufmerksam machen. LGV wird durch die Chlamydia trachomatis Serotypen L1 \u2013 L3 ausgel\u00f6st und kann falsch behandelt zu schweren Komplikationen f\u00fchren. […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Diagnostics\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-22T13:05:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-22T13:05:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2024\/05\/2024-03_website-news_chlamydia.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"930\" \/>\n\t<meta property=\"og:image:height\" content=\"339\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"simonpatasic\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"simonpatasic\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\\\/\"},\"author\":{\"name\":\"simonpatasic\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#\\\/schema\\\/person\\\/cc75e096468dead4da2680d215eda71d\"},\"headline\":\"Meldepflicht Chlamydia trachomatis Serotypen L1- L3\",\"datePublished\":\"2024-05-22T13:05:56+00:00\",\"dateModified\":\"2024-05-22T13:05:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\\\/\"},\"wordCount\":203,\"image\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/2024-03_website-news_chlamydia.jpg\",\"articleSection\":[\"Sonstige\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\\\/\",\"url\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\\\/\",\"name\":\"Meldepflicht Chlamydia trachomatis Serotypen L1- L3 - Clinical Diagnostics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/2024-03_website-news_chlamydia.jpg\",\"datePublished\":\"2024-05-22T13:05:56+00:00\",\"dateModified\":\"2024-05-22T13:05:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#\\\/schema\\\/person\\\/cc75e096468dead4da2680d215eda71d\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/2024-03_website-news_chlamydia.jpg\",\"contentUrl\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/2024-03_website-news_chlamydia.jpg\",\"width\":930,\"height\":339},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/news\\\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Meldepflicht Chlamydia trachomatis Serotypen L1- L3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/\",\"name\":\"Clinical Diagnostics\",\"description\":\"A Division of the R-Biopharm Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/clinical.r-biopharm.com\\\/fr\\\/#\\\/schema\\\/person\\\/cc75e096468dead4da2680d215eda71d\",\"name\":\"simonpatasic\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ece836a5d732f88c095eac6e0cccdde834cf8509c9c57d650e20ad1a0c0637bd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ece836a5d732f88c095eac6e0cccdde834cf8509c9c57d650e20ad1a0c0637bd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ece836a5d732f88c095eac6e0cccdde834cf8509c9c57d650e20ad1a0c0637bd?s=96&d=mm&r=g\",\"caption\":\"simonpatasic\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Meldepflicht Chlamydia trachomatis Serotypen L1- L3 - Clinical Diagnostics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/","og_locale":"de_DE","og_type":"article","og_title":"Meldepflicht Chlamydia trachomatis Serotypen L1- L3 - Clinical Diagnostics","og_description":"Bitte beachten: Der Nachweis der Chlamydia trachomatis Serotypen L1- L3 ist seit September 2022 meldepflichtig Wir m\u00f6chten Sie auf die entscheidende Bedeutung der Differenzierung zwischen herk\u00f6mmlichen Chlamydia trachomatis Infektionen – und LGV (Lymphogranuloma venereum) aufmerksam machen. LGV wird durch die Chlamydia trachomatis Serotypen L1 \u2013 L3 ausgel\u00f6st und kann falsch behandelt zu schweren Komplikationen f\u00fchren. […]","og_url":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/","og_site_name":"Clinical Diagnostics","article_published_time":"2024-05-22T13:05:56+00:00","article_modified_time":"2024-05-22T13:05:57+00:00","og_image":[{"width":930,"height":339,"url":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2024\/05\/2024-03_website-news_chlamydia.jpg","type":"image\/jpeg"}],"author":"simonpatasic","twitter_misc":{"Verfasst von":"simonpatasic","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/#article","isPartOf":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/"},"author":{"name":"simonpatasic","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/cc75e096468dead4da2680d215eda71d"},"headline":"Meldepflicht Chlamydia trachomatis Serotypen L1- L3","datePublished":"2024-05-22T13:05:56+00:00","dateModified":"2024-05-22T13:05:57+00:00","mainEntityOfPage":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/"},"wordCount":203,"image":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/#primaryimage"},"thumbnailUrl":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2024\/05\/2024-03_website-news_chlamydia.jpg","articleSection":["Sonstige"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/","url":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/","name":"Meldepflicht Chlamydia trachomatis Serotypen L1- L3 - Clinical Diagnostics","isPartOf":{"@id":"https:\/\/clinical.r-biopharm.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/#primaryimage"},"image":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/#primaryimage"},"thumbnailUrl":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2024\/05\/2024-03_website-news_chlamydia.jpg","datePublished":"2024-05-22T13:05:56+00:00","dateModified":"2024-05-22T13:05:57+00:00","author":{"@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/cc75e096468dead4da2680d215eda71d"},"breadcrumb":{"@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/#primaryimage","url":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2024\/05\/2024-03_website-news_chlamydia.jpg","contentUrl":"https:\/\/clinical.r-biopharm.com\/wp-content\/uploads\/2024\/05\/2024-03_website-news_chlamydia.jpg","width":930,"height":339},{"@type":"BreadcrumbList","@id":"https:\/\/clinical.r-biopharm.com\/de\/news\/meldepflicht-chlamydia-trachomatis-serotypen-l1-l3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clinical.r-biopharm.com\/de\/"},{"@type":"ListItem","position":2,"name":"Meldepflicht Chlamydia trachomatis Serotypen L1- L3"}]},{"@type":"WebSite","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#website","url":"https:\/\/clinical.r-biopharm.com\/fr\/","name":"Clinical Diagnostics","description":"A Division of the R-Biopharm Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clinical.r-biopharm.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/clinical.r-biopharm.com\/fr\/#\/schema\/person\/cc75e096468dead4da2680d215eda71d","name":"simonpatasic","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/ece836a5d732f88c095eac6e0cccdde834cf8509c9c57d650e20ad1a0c0637bd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ece836a5d732f88c095eac6e0cccdde834cf8509c9c57d650e20ad1a0c0637bd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ece836a5d732f88c095eac6e0cccdde834cf8509c9c57d650e20ad1a0c0637bd?s=96&d=mm&r=g","caption":"simonpatasic"}}]}},"_links":{"self":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/180553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/users\/330"}],"replies":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/comments?post=180553"}],"version-history":[{"count":1,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/180553\/revisions"}],"predecessor-version":[{"id":180554,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/180553\/revisions\/180554"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media\/180541"}],"wp:attachment":[{"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media?parent=180553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/categories?post=180553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/tags?post=180553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}